Enovis Corporation will discuss Q3 2025 financial results on November 6, 2025, via conference call and webcast.
Quiver AI Summary
Enovis Corporation, a medical technology growth company, announced it will host an investor conference call and live webcast to discuss its third quarter 2025 financial results on November 6, 2025, at 8:30 a.m. Eastern Time, with an earnings press release being issued earlier that morning. The call will include a presentation available on Enovis' website, where a link to the live audio webcast will also be posted. Additionally, Enovis executives will participate in fireside chats at the UBS Global Healthcare Conference on November 9 and the Jefferies London Healthcare Conference on November 18. Investors can access the conference call via dial-in numbers and a replay will be available on the website later that day.
Potential Positives
- Enovis Corporation is actively engaging with investors by hosting a conference call and webcast to discuss its third-quarter financial results, indicating transparency and commitment to shareholder communication.
- The participation of senior executives, including the CEO and CFO, in prominent investor conferences highlights the company's proactive approach to investor relations and market visibility.
- The upcoming earnings press release and conference call may provide crucial financial insights, potentially driving investor interest and confidence in Enovis' performance and growth strategy.
- The company's focus on innovation in medical technology and commitment to improving patient outcomes positions it favorably in a competitive market, appealing to impact-driven investors.
Potential Negatives
- Announcement of an upcoming earnings report could indicate potential volatility in stock price, which may concern investors.
- The lack of disclosed financial performance details prior to the investor call can lead to uncertainty and speculation among stakeholders.
- Participation in multiple investor conferences could imply the company is actively seeking to address concerns or questions from investors, potentially indicating current challenges.
FAQ
When will Enovis announce its third quarter 2025 financial results?
Enovis will announce its third quarter 2025 financial results on November 6, 2025, at 8:30 a.m. Eastern Time.
How can I access the Enovis investor conference call?
The investor conference call can be accessed via phone at (800) 715-9871 for U.S. callers or (646) 307-1963 for international callers.
Where can I find the webcast for the Q3 financial results?
The webcast will be available in the "Investors" section of Enovis' website at www.enovis.com.
Who from Enovis will speak at the UBS Global Healthcare Conference?
Damien McDonald, CEO, and Ben Berry, CFO, will speak at the UBS Global Healthcare Conference on November 9, 2025.
What is the purpose of Enovis' upcoming investor conferences?
The investor conferences aim to discuss financial results and engage with the investment community about Enovis' growth and innovations.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$ENOV Insider Trading Activity
$ENOV insiders have traded $ENOV stock on the open market 4 times in the past 6 months. Of those trades, 4 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $ENOV stock by insiders over the last 6 months:
- DANIEL A PRYOR (EVP, Strategy & Business Dev.) purchased 10,000 shares for an estimated $289,000
- DAMIEN MCDONALD (Chief Executive Officer) purchased 6,457 shares for an estimated $199,973
- BRADLEY J TANDY (SVP and Chief Legal Officer) purchased 3,200 shares for an estimated $100,512
- PHILLIP BENJAMIN (BEN) BERRY (SVP, Chief Financial Officer) purchased 2,500 shares for an estimated $74,275
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$ENOV Hedge Fund Activity
We have seen 156 institutional investors add shares of $ENOV stock to their portfolio, and 152 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. removed 6,206,566 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $194,637,909
- DORSEY ASSET MANAGEMENT, LLC added 2,553,180 shares (+inf%) to their portfolio in Q2 2025, for an estimated $80,067,724
- BLACKROCK, INC. added 1,765,671 shares (+24.7%) to their portfolio in Q2 2025, for an estimated $55,371,442
- AMERICAN CENTURY COMPANIES INC added 1,212,365 shares (+34.4%) to their portfolio in Q2 2025, for an estimated $38,019,766
- DIAMOND HILL CAPITAL MANAGEMENT INC removed 1,091,133 shares (-58.3%) from their portfolio in Q2 2025, for an estimated $34,217,930
- ARTEMIS INVESTMENT MANAGEMENT LLP removed 696,118 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $21,830,260
- STATE STREET CORP added 592,505 shares (+31.3%) to their portfolio in Q2 2025, for an estimated $18,580,956
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$ENOV Analyst Ratings
Wall Street analysts have issued reports on $ENOV in the last several months. We have seen 5 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- UBS issued a "Buy" rating on 08/08/2025
- Wells Fargo issued a "Overweight" rating on 08/08/2025
- Canaccord Genuity issued a "Buy" rating on 08/08/2025
- Needham issued a "Buy" rating on 08/07/2025
- JMP Securities issued a "Market Outperform" rating on 05/09/2025
To track analyst ratings and price targets for $ENOV, check out Quiver Quantitative's $ENOV forecast page.
$ENOV Price Targets
Multiple analysts have issued price targets for $ENOV recently. We have seen 6 analysts offer price targets for $ENOV in the last 6 months, with a median target of $52.0.
Here are some recent targets:
- Danielle Antalffy from UBS set a target price of $57.0 on 08/08/2025
- Caitlin Cronin from Canaccord Genuity set a target price of $58.0 on 08/08/2025
- Vik Chopra from Wells Fargo set a target price of $41.0 on 08/08/2025
- Mike Matson from Needham set a target price of $49.0 on 08/07/2025
- Vijay Kumar from Evercore ISI Group set a target price of $46.0 on 07/08/2025
- David Turkaly from JMP Securities set a target price of $55.0 on 05/09/2025
Full Release
Dallas, TX, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (“Enovis” or “the Company”) (NYSE: ENOV), an innovation-driven medical technology growth company, announced today it will host an investor conference call and live webcast to discuss its third quarter 2025 financial results on Thursday, November 6th, 2025, at 8:30 a.m. Eastern Time and issue an earnings press release earlier that morning. A presentation related to the call, as well as a webcast, will be made available on the "Investors" section of Enovis' website at www.enovis.com . Additionally, the company also announced it will participate in the following investor conferences:
- UBS Global Healthcare Conference: Damien McDonald, Chief Executive Officer, and Ben Berry, Chief Financial Officer, will participate in a fireside chat on Monday, November 9th at 2:45 p.m. ET
-
Jefferies London Healthcare Conference:
Damien McDonald, Chief Executive Officer, and Ben Berry, Chief Financial Officer, will participate in a fireside chat on Tuesday, November 18th at 3:30 p.m. GMT (10:30 a.m. ET)
A link to the live audio webcasts, as well as a replay of these events, will be available on the Company’s website under the Investors tab at Events and Presentations.
Third Quarter 2025 Conference Call/Webcast Information
Investors can access the live webcast via a link on the Enovis website. For those planning to participate on the call, please dial (800) 715-9871 (U.S. callers) and (646) 307-1963 (International callers) and use conference ID 1691901. A link to a replay of the call will also be available on the Enovis website later that day.
About Enovis
Enovis Corporation (NYSE: ENOV) is an innovation-driven medical technology growth company dedicated to developing clinically differentiated solutions that generate measurably better patient outcomes and transform workflows. Powered by a culture of continuous improvement, global talent and innovation, the Company’s extensive range of products, services and integrated technologies fuels active lifestyles in orthopedics and beyond. The Company’s shares of common stock are listed in the United States on the New York Stock Exchange under the symbol ENOV. For more information about Enovis, please visit www.enovis.com .
Availability of Information on the Enovis Website
Investors and others should note that Enovis routinely announces material information to investors and the marketplace using SEC filings, press releases, public conference calls, webcasts and the Enovis Investor Relations website. While not all of the information that the Company posts to the Enovis Investor Relations website is of a material nature, some information could be deemed to be material. Accordingly, the Company encourages investors, the media and others interested in Enovis to review the information that it shares on ir.enovis.com.
Kyle Rose
Vice President, Investor Relations
Enovis Corporation
[email protected]
